Etiology And Pathogenesis

  • Represents chronic inflammatory disease manifesting primarily in infancy and adolescence.
  • Cutaneous distribution directly parallels size, distribution, and activity of sebaceous glands.
  • Exact etiology remains unknown.
  • Malassezia furfur (commensal yeast) heavily incriminated in disease pathogenesis.
  • Cutaneous inflammation potentially results from direct fungal action, fungal by-products, or exaggerated host immune response.
  • Adolescent manifestation strictly follows puberty, indicating distinct sex hormone influence.
  • Relationship between infantile and adolescent forms remains unclear; infantile disease does not predict adolescent recurrence.

Clinical Manifestations

Infantile Seborrheic Dermatitis

  • Onset typically occurs within first 4 weeks of life.
  • Illness remains self-limiting, generally resolving by 12 weeks to 1 year of age.
  • Initial manifestation frequently involves diffuse or focal scaling and crusting of scalp, clinically termed cradle cap.
  • Characterized by yellow-orange, greasy scales and crusts overlying erythema.
  • Lesions frequently expand to involve face, neck, retroauricular areas, axillae, umbilicus, and diaper area.
  • Cutaneous lesions generally remain nonpruritic in infants.
  • Postinflammatory pigmentary changes (hypopigmentation) commonly observed in darker skin tones.
  • Intractable seborrhea-like dermatitis associated with chronic diarrhea and failure to thrive mandates urgent evaluation for systemic immune dysfunction.
  • Chronic treatment-resistant pattern occasionally indicates underlying Langerhans cell histiocytosis.

Adolescent Seborrheic Dermatitis

  • Disease onset universally follows puberty.
  • Follows chronic relapsing course, generally lacking spontaneous resolution.
  • Disease remains more localized, confined primarily to scalp, chest, and intertriginous areas.
  • Scalp manifestations vary from diffuse brawny scaling to focal thick, oily, yellow crusts with underlying erythema.
  • Frequently involves marginal blepharitis and external auditory canal inflammation.
  • Severe cases exhibit prominent erythema and scaling at frontal hairline, medial eyebrows, nasolabial folds, and retroauricular folds.
  • Red, scaly plaques frequently appear in axillae, inguinal region, gluteal cleft, and umbilicus.
  • Extremity plaques often appear more eczematous, less erythematous, and poorly demarcated.
  • Pruritus highly variable, ranging from absent to marked.
  • Accompanying hair loss remains distinctly uncommon.

Associated Systemic Conditions

  • Represents frequent cutaneous manifestation of Acquired Immunodeficiency Syndrome.
  • Human Immunodeficiency Virus infected patients exhibit thick, greasy scalp scales and large hyperkeratotic erythematous plaques on face, chest, and genitals.

Differential Diagnosis

Diagnostic EntityDistinguishing Clinical Features
Atopic DermatitisCharacterized by acute weeping, severe pruritus; often clinically indistinguishable from seborrheic dermatitis in early infancy.
PsoriasisExhibits bright red, scaly, well-demarcated plaques; highly persistent; strong family history common.
Langerhans Cell HistiocytosisPresents with treatment-resistant, infiltrative, crusted, hemorrhagic papules in groin, axillae, scalp; accompanied by systemic signs including hepatosplenomegaly and anemia.
CandidiasisInvolves intertriginous and convex surfaces; features bright-red plaques with diagnostic satellite pustules.
Irritant Diaper DermatitisStrictly spares intertriginous creases; localized strictly to convex contact surfaces.

Therapeutic Management Protocol

Infantile Disease Management

Therapeutic ModalitySpecific Clinical Recommendations
General Skin CareEmollients, baby oil, gentle shampooing utilizing nonmedicated baby shampoo.
Mechanical Scale RemovalPretreatment with oil followed by gentle brushing removes thick cradle cap crusts effectively.
Refractory LesionsApply 2% ketoconazole shampoo or cream twice daily.
Inflammatory LesionsShort course of mild, low-potency topical corticosteroids applied once daily for 1 week.
Steroid Sparing AgentsTopical calcineurin inhibitors (pimecrolimus or tacrolimus) hasten clinical subsidence.

Adolescent Disease Management

Target Anatomical AreaSpecific Pharmacologic Interventions
Scalp (First-Line Therapy)Antifungal shampoos (selenium sulfide, ketoconazole, ciclopirox, zinc pyrithione, salicylic acid, tar) utilized several times weekly to daily.
Scalp (Inflamed Lesions)Mid-potency topical corticosteroids (fluocinolone 0.01% oil or triamcinolone 0.1% lotion) applied once daily for 2-4 weeks.
Facial LesionsLow-potency topical corticosteroid cream combined continuously with topical antifungals (ketoconazole 2% cream/shampoo).
Trunk And Extremity LesionsMid-potency topical corticosteroid cream combined continuously with topical antifungals.
Second-Line OptionsTopical calcineurin inhibitors; potent keratolytic agents including urea.
Severe Refractory DiseaseOral antifungal agents utilized in severe adult cases; comprehensive pediatric data remains lacking.
Long-Term MaintenanceAntifungal shampoo utilized strictly twice-weekly significantly reduces clinical relapse risk.